Your browser is no longer supported. Please, upgrade your browser.
APTO Aptose Biosciences Inc. monthly Stock Chart
APTO [NASD]
Aptose Biosciences Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own20.40% Shs Outstand85.86M Perf Week-2.55%
Market Cap550.19M Forward P/E- EPS next Y-0.75 Insider Trans-2.21% Shs Float84.34M Perf Month29.94%
Income-48.20M PEG- EPS next Q-0.17 Inst Own35.10% Short Float2.70% Perf Quarter11.27%
Sales- P/S- EPS this Y39.40% Inst Trans0.80% Short Ratio2.37 Perf Half Y-10.26%
Book/sh1.50 P/B4.08 EPS next Y37.20% ROA-46.60% Target Price4.72 Perf Year138.13%
Cash/sh1.48 P/C4.15 EPS next 5Y- ROE-49.50% 52W Range2.47 - 9.25 Perf YTD7.94%
Dividend- P/FCF- EPS past 5Y4.80% ROI- 52W High-33.86% Beta1.64
Dividend %- Quick Ratio24.60 Sales past 5Y- Gross Margin- 52W Low147.27% ATR0.40
Employees31 Current Ratio24.60 Sales Q/Q- Oper. Margin- RSI (14)53.90 Volatility7.65% 7.13%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.00% Profit Margin- Rel Volume1.61 Prev Close6.31
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume960.81K Price6.12
Recom2.00 SMA206.32% SMA509.18% SMA200-1.53% Volume1,546,909 Change-3.01%
Oct-19-20Initiated Cantor Fitzgerald Overweight $10
Sep-22-20Initiated Alliance Global Partners Buy $12
Feb-20-20Initiated Maxim Group Buy $16
Feb-06-20Reiterated H.C. Wainwright Buy $6 → $9
Jan-09-20Initiated Piper Sandler Overweight $10
Mar-01-19Initiated RBC Capital Mkts Outperform $6
Nov-16-18Initiated B. Riley FBR Buy $5
Dec-13-17Reiterated H.C. Wainwright Buy
Oct-23-17Resumed ROTH Capital Buy $5
Sep-07-17Upgrade H.C. Wainwright Neutral → Buy $1 → $4
Jun-08-17Initiated Rodman & Renshaw Neutral $1
Dec-04-20 08:59AM  
08:45AM  
Dec-03-20 10:04AM  
Dec-02-20 06:03PM  
03:52PM  
08:54AM  
Dec-01-20 08:55AM  
07:30AM  
Nov-17-20 10:00AM  
Nov-10-20 04:01PM  
03:15PM  
Nov-05-20 07:02AM  
Nov-04-20 10:17AM  
Oct-27-20 04:01PM  
Oct-20-20 10:26AM  
Oct-19-20 07:00AM  
Oct-14-20 09:52PM  
Sep-15-20 07:30AM  
Sep-09-20 07:30AM  
Sep-02-20 08:50AM  
Aug-28-20 06:53AM  
Aug-26-20 10:35AM  
Aug-06-20 07:30AM  
Aug-04-20 04:01PM  
Jul-21-20 04:01PM  
04:01PM  
Jul-16-20 03:31PM  
Jul-15-20 10:49PM  
04:01PM  
Jun-29-20 07:01AM  
Jun-27-20 09:10PM  
Jun-23-20 10:50AM  
Jun-12-20 07:00AM  
Jun-02-20 05:49PM  
May-14-20 09:00AM  
May-09-20 10:28AM  
May-07-20 07:30AM  
May-06-20 09:31PM  
May-05-20 04:17PM  
04:00PM  
03:00PM  
May-03-20 07:30PM  
Apr-27-20 03:29PM  
09:00AM  
Apr-24-20 07:30AM  
Apr-21-20 07:30AM  
Apr-14-20 12:00PM  
Mar-10-20 04:02PM  
03:00PM  
Feb-25-20 07:31AM  
Feb-21-20 08:35AM  
Feb-05-20 11:52AM  
Jan-29-20 07:30AM  
07:01AM  
Jan-28-20 02:36PM  
Jan-17-20 08:44AM  
Jan-07-20 07:30AM  
Dec-19-19 04:02PM  
03:50PM  
Dec-17-19 08:00AM  
07:56AM  
Dec-16-19 04:19PM  
Dec-09-19 11:00AM  
Dec-07-19 11:00AM  
Dec-04-19 07:30AM  
Dec-02-19 07:30AM  
Nov-11-19 08:26AM  
Nov-07-19 07:30AM  
Nov-06-19 09:54AM  
Nov-05-19 04:02PM  
Oct-22-19 07:00AM  
Oct-10-19 07:30AM  
Sep-16-19 07:30AM  
Sep-12-19 06:46AM  
Aug-06-19 04:00PM  
Jul-30-19 07:30AM  
Jul-23-19 07:30AM  
Jul-16-19 07:05AM  
Jul-08-19 10:24AM  
Jul-05-19 08:38AM  
Jun-14-19 07:00AM  
Jun-04-19 04:02PM  
Jun-03-19 09:00AM  
08:38AM  
May-31-19 08:00AM  
May-30-19 09:01AM  
May-29-19 04:22PM  
May-24-19 05:43PM  
May-16-19 10:02AM  
May-13-19 08:15AM  
May-10-19 07:24PM  
May-07-19 05:25PM  
04:01PM  
Apr-24-19 07:30AM  
Apr-23-19 07:30AM  
Apr-02-19 07:00AM  
Mar-25-19 07:02AM  
Mar-12-19 05:18PM  
04:02PM  
Mar-07-19 07:00AM  
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chow Gregory K.Executive VP & CFOJul 10Sale6.05126,668766,341232,846Jul 10 06:57 PM
Rice William G.Chair, President & CEOJul 10Sale6.05168,8911,021,791297,523Jul 10 06:55 PM
Marango JotinSenior VP, Chief Bus. OfficerJul 10Sale6.0562,835380,152116,219Jul 10 06:53 PM
Marango JotinSenior VP, Chief Bus. OfficerJul 02Sale6.3420,946132,793179,054Jul 02 08:08 PM
Whitehead WarrenDirectorJun 24Option Exercise1.9412,00023,30057,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 24Sale6.7417,000114,66040,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 23Option Exercise1.5113,00019,66363,000Jun 25 06:38 PM
Whitehead WarrenDirectorJun 23Sale7.1118,000127,89045,000Jun 25 06:38 PM
Rice William G.Chair, President & CEOMar 25Buy5.823,40019,803466,414Mar 26 01:10 PM